Redeye revises its estimates and valuation on the back of the Q4 2023 report, which came in below our expectations. While the company continues to replace low-margin sales from SDD with recurring revenues, the financial leverage remains on the high end.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases